| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 13
| Issue : 4 | Page : 172-175 |
|
|
Blood and blood products to support allogeneic hematopoietic progenitor cell transplant recipients at king abdulaziz medical city-Riyadh – Transfusion medicine services
Ahmed Al Harbi, Abdullah Al-Anazi, Faisal Al Saqri, Haya Wasel
Department of Pathology and Lab Medicine, King Abdullah Specialist Children Hospital, King Abdulaziz Medical City-CR, Ministry of National Guard, Riyadh, Saudi Arabia
Correspondence Address:
Mr. Ahmed Al Harbi
Department of Pathology and Lab Medicine, King Abdullah Specialist Children Hospital, King Abdulaziz Medical City-Riyadh, Ministry of National Guard, Riyadh
Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/joah.joah_115_21
|
|
|
Hematopoietic progenitor cell transplant (HPCT) is found throughout the body. HPCT is a set of undifferentiated cells that are capable of indefinite self-renewal and generation of a functional progeny of highly specialized cells. Allogeneic HPCT presents a distinct set of challenges for blood banks and transfusion services. When considering transfusion for an HPCT recipient, one has to take into account not only the complexities associated with the patient's underlying condition, but also potential problems associated with recipient alloantibodies, donor passenger lymphocytes, and the conversion of blood group substance after successful allogeneic HPCT. For an allogeneic HPCT recipient, it is vital that the blood transfusion service keep a detailed record of the donor and recipient's that include donor blood group and antibody screening results and recipient's pre- and posttransplant blood group and antibody screening results. The management of nonidentical and incompatible HPCT requires a unique strategies when major, minor, and bidirectional differences exist which have the potentiality to improve patient outcomes and allow for effective management of the blood and blood products inventory.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
